- Home
- SOTK vs UNCY Comparison
SOTK vs UNCY Comparison
Compare SOTK & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOTK
- UNCY
- Stock Information
- Founded
- SOTK 1975
- UNCY 2016
- Country
- SOTK United States
- UNCY United States
- Employees
- SOTK N/A
- UNCY N/A
- Industry
- SOTK Industrial Machinery/Components
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- SOTK Technology
- UNCY Health Care
- Exchange
- SOTK Nasdaq
- UNCY Nasdaq
- Market Cap
- SOTK 58.5M
- UNCY 91.0M
- IPO Year
- SOTK 1987
- UNCY 2021
- Fundamental
- Price
- SOTK $3.66
- UNCY $4.95
- Analyst Decision
- SOTK Hold
- UNCY Strong Buy
- Analyst Count
- SOTK 1
- UNCY 4
- Target Price
- SOTK N/A
- UNCY $63.75
- AVG Volume (30 Days)
- SOTK 4.9K
- UNCY 1.2M
- Earning Date
- SOTK 07-10-2025
- UNCY 08-13-2025
- Dividend Yield
- SOTK N/A
- UNCY N/A
- EPS Growth
- SOTK N/A
- UNCY N/A
- EPS
- SOTK 0.09
- UNCY N/A
- Revenue
- SOTK $20,606,116.00
- UNCY N/A
- Revenue This Year
- SOTK N/A
- UNCY N/A
- Revenue Next Year
- SOTK $9.53
- UNCY $1,458.53
- P/E Ratio
- SOTK $40.89
- UNCY N/A
- Revenue Growth
- SOTK N/A
- UNCY N/A
- 52 Week Low
- SOTK $3.50
- UNCY $2.02
- 52 Week High
- SOTK $6.05
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- SOTK 50.01
- UNCY 43.02
- Support Level
- SOTK $3.63
- UNCY $4.31
- Resistance Level
- SOTK $3.78
- UNCY $5.55
- Average True Range (ATR)
- SOTK 0.13
- UNCY 0.76
- MACD
- SOTK 0.00
- UNCY -0.10
- Stochastic Oscillator
- SOTK 52.38
- UNCY 16.26
About SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.